상처 치료 시장 : 제품 유형별, 창상 유형별, 제품 사용성별, 최종 사용자별, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Wound Care Market is projected to grow by USD 36.39 billion at a CAGR of 8.04% by 2032.

Wound care is shifting from episodic treatment to evidence-based chronic wound management as diabetes, obesity, vascular disease, aging, and surgical volumes increase global demand. The International Diabetes Federation reported 537 million adults living with diabetes in 2021, while WHO data show rapid population aging, both of which expand the risk pool for diabetic foot ulcers, venous leg ulcers, pressure injuries, and non-healing surgical wounds.

Demand is concentrated in advanced wound care products such as antimicrobial dressings, foam and hydrocolloid dressings, alginate dressings, negative pressure wound therapy, skin substitutes, and digital wound assessment tools. Healthcare systems are prioritizing faster closure, infection prevention, lower readmissions, and home-based care, making clinical outcomes, evidence quality, and total cost of care central to purchasing decisions.

Transformative Shifts in the Wound Care Landscape

The wound care landscape is being reshaped by the move from conventional gauze toward moist wound healing, bioactive dressings, antimicrobial technologies, and device-enabled therapies. Clinical guidance increasingly emphasizes early risk assessment, debridement, infection control, pressure redistribution, nutrition, vascular evaluation, and multidisciplinary diabetic foot programs to prevent amputations and avoidable hospital use.

Site of care is also changing. Hospitals remain critical for acute and complex wounds, but ambulatory wound centers, skilled nursing facilities, long-term care facilities, and home healthcare are expanding as payers and providers seek lower-cost settings. This shift rewards solutions that combine clinical efficacy, ease of use, supply reliability, patient adherence, and reimbursement support.

Cumulative Impact of Artificial Intelligence in Wound Care

Artificial intelligence is adding measurable potential to wound care through image-based wound measurement, tissue classification, healing trajectory prediction, documentation automation, and remote monitoring. FDA listings of AI and machine-learning-enabled medical devices and peer-reviewed studies in digital imaging show that AI can improve consistency in wound assessment when supported by validated datasets and clinician oversight.

The cumulative impact is operational as well as clinical. AI can reduce variability between clinicians, support earlier escalation for infected or stalled wounds, and create structured data for value-based care. Adoption will depend on data quality, interoperability with electronic health records, cybersecurity, equity across skin tones, workflow fit, and compliance with medical device regulations.

Key Regional Insights

Asia-Pacific is a pivotal wound care region because China, India, Japan, Australia, and South Korea combine large diabetic populations, aging demographics, expanding hospital infrastructure, and rising use of advanced dressings and digital health. North America remains highly advanced, led by the United States and Canada, where specialized wound centers, reimbursement pathways, negative pressure wound therapy, infection prevention protocols, and digital wound documentation are widely used across hospital, outpatient, and home-care settings.

Latin America, led by Brazil and Mexico, is adopting advanced wound care as public and private systems address diabetes-related complications, surgical wounds, and pressure injuries. Europe benefits from strong clinical guidelines, health technology assessment processes, and established wound care pathways in Germany, France, Italy, Spain, and the United Kingdom, while the Middle East is supported by GCC hospital investment, diabetes programs, and digital health initiatives. Africa shows substantial long-term need as diabetes, trauma, burns, and infection-related wounds create demand, with access, affordability, supply continuity, and clinician training shaping adoption.

Key Group Insights

ASEAN markets are building wound care capacity through hospital modernization, universal health coverage initiatives, and diabetes management programs, with demand rising for cost-effective antimicrobial dressings, foam dressings, and home-care solutions. The GCC is investing in specialty hospitals, diabetes centers, and digital health platforms, supporting adoption of advanced wound care, remote wound monitoring, and multidisciplinary chronic wound services.

The European Union offers a sophisticated but regulated environment where MDR compliance, health technology assessment, clinical evidence, and procurement criteria influence market access. BRICS countries represent scale, manufacturing potential, and unmet chronic wound burden, particularly where diabetes, urbanization, and uneven access to specialist care increase pressure on health systems. G7 markets are innovation centers for biologics, negative pressure systems, antimicrobial technologies, and AI wound assessment, while NATO countries benefit from trauma care expertise, emergency preparedness, and military medicine pathways that support advanced wound management practices.

Key Country Insights

The United States leads in advanced wound care utilization, supported by specialized wound centers, high diabetes prevalence, broad use of negative pressure wound therapy, and digital documentation, while Canada emphasizes evidence-based procurement, provincial access, and care coordination across hospitals, community care, and long-term care. Mexico and Brazil are expanding chronic wound services as diabetes, obesity, and surgical care demand increase the need for infection prevention, advanced dressings, and clinician training.

In Europe, the United Kingdom, Germany, France, Italy, and Spain prioritize guideline-driven care, pressure injury prevention, antimicrobial stewardship, and cost-effectiveness across hospital and community pathways, while Russia maintains demand across hospital, trauma, burns, and surgical wound care settings. China and India combine major diabetes burdens with expanding hospital networks and domestic manufacturing, creating strong need for affordable advanced dressings, diabetic foot ulcer care, and scalable wound management models.

Japan and South Korea emphasize aging-related wound care, pressure injury prevention, infection control, and technology integration in acute and long-term care. Australia has strong clinical governance, a significant aged-care burden, and remote care needs, making telehealth-enabled wound management, mobile nursing support, and standardized assessment relevant across urban, rural, and aged-care settings.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize products that demonstrate faster healing, lower infection risk, fewer dressing changes, improved patient comfort, and reduced total treatment cost. Evidence packages should include real-world outcomes, subgroup performance in diabetic foot ulcers, venous leg ulcers, pressure injuries, burns, and surgical wounds, and health economic data aligned with payer and procurement expectations.

Commercial strategy should combine clinician education, reimbursement support, digital documentation, and partnerships with wound centers, home health providers, long-term care facilities, and diabetes programs. Organizations should also strengthen supply resilience, antimicrobial stewardship, inclusive AI validation, cybersecurity controls, post-market surveillance, and regulatory readiness for the FDA, EU MDR, and other national authorities.

Research Methodology

This executive summary is grounded in secondary research from verified sources, including WHO, the International Diabetes Federation, CDC, OECD, World Bank health indicators, national health agencies, medical device regulators, clinical guidelines, and peer-reviewed wound care literature. Insights were cross-checked against disease burden, demographics, care setting trends, regulatory evidence, and documented adoption of advanced wound care technologies.

The methodology emphasizes triangulation across epidemiology, clinical practice, reimbursement dynamics, technology adoption, healthcare infrastructure, and regional access patterns. Market interpretation excludes unsupported claims and prioritizes observable indicators such as diabetes prevalence, aging, surgical care demand, pressure injury prevention priorities, regulatory pathways, and evidence-backed use of advanced wound care products and digital wound care tools.

Conclusion

The wound care market is entering a more outcomes-driven phase as chronic wounds place sustained pressure on healthcare systems. Advanced dressings, negative pressure wound therapy, skin substitutes, antimicrobial solutions, and digital wound platforms are gaining strategic importance where they can improve healing, reduce complications, standardize documentation, and support care outside the hospital.

Artificial intelligence, regional healthcare investment, and stronger clinical evidence will define competitive advantage. Organizations that connect wound care innovation with affordability, compliance, training, access, and measurable patient outcomes will be best positioned in the evolving global wound care ecosystem.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Wound Care Market, by Product Type

• 7.1. Dressings
  • 7.1.1. Alginate Dressings
  • 7.1.2. Collagen Dressings
  • 7.1.3. Film Dressings
  • 7.1.4. Foam Dressings
  • 7.1.5. Hydrocolloid Dressings
  • 7.1.6. Hydrogel Dressings
• 7.2. Wound Care Consumables
  • 7.2.1. Bandages
  • 7.2.2. Gauze
  • 7.2.3. Gloves
  • 7.2.4. Tapes
• 7.3. Wound Care Equipment
  • 7.3.1. Hyperbaric Oxygen Therapy
  • 7.3.2. Negative Pressure Wound Therapy
  • 7.3.3. Photodynamic Therapy
  • 7.3.4. Ultrasound Therapy
• 7.4. Wound Closure Devices
  • 7.4.1. Surgical Staplers
  • 7.4.2. Sutures
  • 7.4.3. Tissue Adhesives

8. Wound Care Market, by Wound Type

• 8.1. Acute Wounds
  • 8.1.1. Burn Wounds
  • 8.1.2. Surgical Wounds
  • 8.1.3. Traumatic Wounds
• 8.2. Chronic Wounds
  • 8.2.1. Diabetic Foot Ulcers
  • 8.2.2. Pressure Ulcers
  • 8.2.3. Venous Leg Ulcers

9. Wound Care Market, by Product Usability

• 9.1. Single-Use
• 9.2. Reusable

10. Wound Care Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Home Care
• 10.3. Hospitals
• 10.4. Long Term Care Facilities
• 10.5. Specialty Clinics

11. Wound Care Market, by Distribution Channel

• 11.1. Direct Sales
• 11.2. E-Commerce
• 11.3. Hospital Pharmacies
• 11.4. Retail Pharmacies

12. Wound Care Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Wound Care Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Wound Care Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Advanced Medical Solutions Group PLC
• 16.2. Avery Dennison Corporation
• 16.3. B. Braun SE
• 16.4. Baxter International Inc.
• 16.5. BDK Industrial Products Ltd.
• 16.6. Biogennix, LLC
• 16.7. Cardinal Health, Inc.
• 16.8. Coloplast A/S
• 16.9. Convatec Limited
• 16.10. DermaRite Industries, LLC
• 16.11. Essity AB
• 16.12. Healogics, LLC
• 16.13. Integra LifeSciences Corporation
• 16.14. Johnson & Johnson
• 16.15. Laboratoires Urgo
• 16.16. Lohmann & Rauscher GmbH & Co. KG
• 16.17. Lotus Surgicals by TI Medical
• 16.18. Medline Industries, Inc.
• 16.19. Medtronic PLC
• 16.20. MiMedx Group, Inc.
• 16.21. Molnlycke Health Care AB
• 16.22. Nichiban Co., Ltd.
• 16.23. Organogenesis Inc.
• 16.24. Paul Hartmann AG
• 16.25. Plastod S.p.A
• 16.26. PolyNovo Limited
• 16.27. Smith & Nephew PLC
• 16.28. Solventum Corporation
• 16.29. Zimmer Biomet Holdings, Inc.